Open an account

Exagen

XGN · NASDAQ

$7.41−$0.02 (−0.27%)TodayMarket closed ·
Prev close $7.43

About XGN

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 216 full-time employees. The company went IPO on 2019-09-19. The firm is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.

Employees
216
Headquarters
Vista, California
Listed
Sep 19, 2019
Sector
Health Care
Industry
Biotechnology
Website
exagen.com

XGN key statistics

Market cap
112.83M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
380.61K
Volume
425.30K
Open price
$7.56
High today
$7.61
Low today
$7.35
52 Week high
$12.23
52 Week low
$2.59

Exagen (XGN) at a glance

Exagen (XGN) last traded at $7.41, with a market cap of 112.83M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $7.35 and $7.61. The current price is 0.8% above the day's low and 2.6% below its high.

Volume so far is 425.30K shares, in line with the average of 380.61K shares a day.

Over the past year Exagen has ranged from $2.59 to $12.23, and now sits 50% of the way up that range.

Exagen met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.13 per share against an estimate of -$0.1919.

The average analyst price target is $10.35, 39.6% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 8 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $10.35
Low
$9.09
Now
$7.41
High
$12.60

XGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 15.5% on average.

  1. Q3 FY24: reported -$0.28 per share against an estimate of -$0.2929
  2. Q4 FY24: reported -$0.20 per share against an estimate of -$0.2626
  3. Q1 FY25: reported -$0.20 per share against an estimate of -$0.2037
  4. Q2 FY25: reported -$0.176 per share against an estimate of -$0.1397
  5. Q3 FY25: reported -$0.31 per share against an estimate of -$0.1591
  6. Q4 FY25: reported -$0.20 per share against an estimate of -$0.1919
  7. Q1 FY26: reported -$0.20 per share against an estimate of -$0.2357
  8. Q2 FY26: reported -$0.13 per share against an estimate of -$0.1919

XGN news

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • 4 Analysts Have This To Say About Exagen

  • A Peek at Exagen's Future Earnings

  • Demystifying Exagen: Insights From 5 Analyst Reviews

  • Beyond The Numbers: 4 Analysts Discuss Exagen Stock

Similar companies

Companies in the same industry as Exagen

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.